3 Stocks Pushing The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 1 points (0.0%) at 17,689 as of Wednesday, Nov. 19, 2014, 3:25 PM ET. The NYSE advances/declines ratio sits at 1,199 issues advancing vs. 1,792 declining with 180 unchanged.

The Drugs industry as a whole closed the day down 0.8% versus the S&P 500, which was down 0.3%. Top gainers within the Drugs industry included Aurinia Pharmaceuticals ( AUPH), up 9.1%, Prima Biomed ( PBMD), up 2.0%, Reliv' International ( RELV), up 8.4%, EntreMed ( ENMD), up 2.0% and Acura Pharmaceuticals ( ACUR), up 5.6%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

EntreMed ( ENMD) is one of the companies that pushed the Drugs industry higher today. EntreMed was up $0.03 (2.0%) to $1.57 on average volume. Throughout the day, 18,471 shares of EntreMed exchanged hands as compared to its average daily volume of 20,800 shares. The stock ranged in a price between $1.53-$1.59 after having opened the day at $1.53 as compared to the previous trading day's close of $1.54.

EntreMed has a market cap of $47.1 million and is part of the health care sector. Shares are down 7.8% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Reliv' International ( RELV) was up $0.10 (8.4%) to $1.29 on heavy volume. Throughout the day, 188,052 shares of Reliv' International exchanged hands as compared to its average daily volume of 16,800 shares. The stock ranged in a price between $1.21-$1.35 after having opened the day at $1.21 as compared to the previous trading day's close of $1.19.

Reliv' International, Inc. develops, manufactures, and markets nutritional supplements that promote basic nutrition, weight loss, athletic performance, digestive health, women's health, anti-aging, and healthy energy. Reliv' International has a market cap of $14.8 million and is part of the health care sector. Shares are down 57.6% year-to-date as of the close of trading on Tuesday. Currently there are no analysts who rate Reliv' International a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Reliv' International as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income.

Highlights from TheStreet Ratings analysis on RELV go as follows:

  • Although RELV's debt-to-equity ratio of 0.23 is very low, it is currently higher than that of the industry average. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.80 is somewhat weak and could be cause for future problems.
  • The gross profit margin for RELIV INTERNATIONAL INC is currently very high, coming in at 79.27%. Regardless of RELV's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 1.15% trails the industry average.
  • RELV, with its decline in revenue, underperformed when compared the industry average of 5.4%. Since the same quarter one year prior, revenues fell by 13.4%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
  • RELIV INTERNATIONAL INC's earnings per share declined by 50.0% in the most recent quarter compared to the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, RELIV INTERNATIONAL INC reported lower earnings of $0.06 versus $0.10 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Personal Products industry. The net income has significantly decreased by 43.3% when compared to the same quarter one year ago, falling from $0.29 million to $0.17 million.

You can view the full analysis from the report here: Reliv' International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Aurinia Pharmaceuticals ( AUPH) was another company that pushed the Drugs industry higher today. Aurinia Pharmaceuticals was up $0.30 (9.1%) to $3.60 on light volume. Throughout the day, 640 shares of Aurinia Pharmaceuticals exchanged hands as compared to its average daily volume of 4,200 shares. The stock ranged in a price between $3.52-$3.60 after having opened the day at $3.52 as compared to the previous trading day's close of $3.30.

Aurinia Pharmaceuticals has a market cap of $110.5 million and is part of the health care sector. Shares are down 0.6% year-to-date as of the close of trading on Tuesday.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss